Live Feed

Cushman & Wakefield managing director joins Corvex — will source the sites and power behind the company's expanding AI Factory platformARLINGTON, Va., Aug. 28, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced that Garrett Brams has joined the company to lead its data center sourcing and development strategy. Brams will oversee the sourcing, evaluation, leasing, and development of mission-critical data center projects supporting Corvex's expanding AI Factory platform. This will strengthen the company's access

4 - RENN Fund, Inc. (0000919567) (Issuer)

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including breast cancer. This growing body of

New Agency Brings Together OM's Hearts & Science and Mediahub to Create a New 40-Market Global Network Hearts United debuts as a leader in new business, outperforming its competitors globally and in EMEA, and topping the US ranking NEW YORK, Aug. 28, 2026 /CNW/ -- Omnicom Media, an Omnicom (NYSE:OMC) Connected Capability, today officially launched Hearts United, a new global media agency created through the combination of its Hearts & Science and Mediahub networks. Bringing together two high-growth challenger organizations with complementary capabilities, cultures and geographic strengths, Hearts United is built to help ambitio

4 - RENN Fund, Inc. (0000919567) (Issuer)

4 - DONALDSON Co INC (0000029644) (Issuer)

4 - ELLSWORTH GROWTH & INCOME FUND LTD (0000793040) (Issuer)

4 - Gabelli Healthcare & WellnessRx Trust (0001391437) (Issuer)

4 - BlackRock ESG Capital Allocation Term Trust (0001864843) (Issuer)

4 - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Issuer)

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose- -CTX310 was well tolerated with no treatment-related serious adverse events, no ≥Grade 3 changes in liver transaminases, and no additional treatment-related adverse events since the previous update- -Findings simultaneously published in The New England Jour

4 - NAPCO SECURITY TECHNOLOGIES, INC (0000069633) (Issuer)

Northpointe Bancshares, Inc. (NYSE:NPB) (the "Company") and its wholly owned subsidiary, Northpointe Bank (the "Bank"), today announced that Joseph (JB) Long will join as Executive Vice President, Chief Operating Officer and Chief Credit Officer. Mr. Long brings over 30 years of leadership experience in operations, balance sheet growth strategies, capital markets, revenue enhancement and corporate development within the banking and mortgage industries. Most recently, he served as Chief Banking & Capital Markets Officer at Cenlar FSB, where he oversaw portfolio risk management, banking operations, capital markets and strategic development initiatives. Earlier in his career, he spent more t

4 - APTARGROUP, INC. (0000896622) (Issuer)

4 - CHAIN BRIDGE BANCORP INC (0001392272) (Issuer)

4 - SCOTTS MIRACLE-GRO CO (0000825542) (Issuer)

DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ:NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration. On August 12, NeOnc reported positive topline results from the NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company reported 48.9% six-month progression-free survival, substantially above the prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall surv

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically "cold" tumors Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C

BOCA RATON, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. ("the Company" or "NewtekOne") (NASDAQ:NEWT) announced updated earnings guidance for 2026 and 2027. The Company now expects 2026 EPS in a range of $1.70-$1.80 and 2027 EPS in a range of $2.00-$2.20, which reflects a decision to hold more guaranteed portions of SBA 7(a) loans on its balance sheet than the Company has historically. As a result, going forward, net interest income ("NII") is expected to grow at a faster pace than noninterest income, with NII representing an increasingly larger portion of total revenue. Barry Sloane, Chairman, CEO, and President of NewtekOne, commented, "We indicated during our 2Q26 earnings c

Evercore ISI reiterated coverage of Amazon with a rating of Outperform and set a new price target of $355.00 from $315.00 previously